1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xvivo Perfusion AB (publ)
  6. Summary
    XVIVO   SE0004840718

XVIVO PERFUSION AB (PUBL)

(XVIVO)
  Report
Delayed Nasdaq Stockholm  -  05/20 11:29:50 am EDT
236.50 SEK   -7.80%
05/19CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologies
AQ
05/19Chu Toulouse in France Starts Liver and Lung Perfusion Programs Using XVIVO Technologies
CI
05/18XVIVO to advance their digital transformation journey in partnership with the world-leading Cleveland Clinic to increase the number of successful lung transplants
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
228(c) 238.5(c) 248(c) 256.5(c) 236.5(c) Last
16 762 10 717 15 171 21 548 22 328 Volume
+1.11% +4.61% +3.98% +3.43% -7.80% Change
More quotes
Estimated financial data (e)
Sales 2022 390 M 39,2 M 39,2 M
Net income 2022 18,3 M 1,84 M 1,84 M
Net cash position 2022 292 M 29,3 M 29,3 M
P/E ratio 2022 319x
Yield 2022 -
Sales 2023 533 M 53,5 M 53,5 M
Net income 2023 43,6 M 4,38 M 4,38 M
Net cash position 2023 316 M 31,7 M 31,7 M
P/E ratio 2023 136x
Yield 2023 -
Capitalization 6 976 M 700 M 700 M
EV / Sales 2022 17,1x
EV / Sales 2023 12,5x
Nbr of Employees 118
Free-Float 72,0%
More Financials
Company
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale... 
More about the company
Ratings of Xvivo Perfusion AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about XVIVO PERFUSION AB (PUBL)
05/19CHU Toulouse in France starts liver and lung perfusion programs using XVIVO technologie..
AQ
05/19Chu Toulouse in France Starts Liver and Lung Perfusion Programs Using XVIVO Technologie..
CI
05/18XVIVO to advance their digital transformation journey in partnership with the world-lea..
AQ
05/18Xvivo Perfusion AB Announces to Advance Their Digital Transformation Journey in Partner..
CI
05/12Reimbursement established for lung and liver transplant in the Netherlands based on res..
AQ
05/04XVIVO has executed agreements with leading US hospitals and delivered the first Kidney ..
AQ
05/04Xvivo Perfusion AB Has Executed Agreements with Leading US Hospitals and Delivered the ..
CI
04/27XVIVO submits an IDE application to US FDA for its innovative heart technology – ..
AQ
04/27Xvivo Submits an Ide Application to US FDA for Its Innovative Heart Technology - A Sign..
CI
04/27Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 27-AP..
CI
04/26Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
AQ
04/25TRANSCRIPT : Xvivo Perfusion AB, Q1 2022 Earnings Call, Apr 25, 2022
CI
04/25XVIVO presents interim report January-March 2022
AQ
04/25Xvivo Perfusion AB Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/21AddLife Names New President/CEO
MT
More news
News in other languages on XVIVO PERFUSION AB (PUBL)
05/19Le Chu Toulouse en France lance des programmes de perfusion du foie et des poumons en u..
05/18Xvivo Perfusion AB (publ) annonce l'avancement de son parcours de transformation numéri..
05/04Xvivo Perfusion AB (Publ) a conclu des accords avec des hôpitaux américains de premier ..
04/27Xvivo soumet une demande d'Ide à la FDA américaine pour sa technologie cardiaque innova..
04/25Xvivo Perfusion AB (publ) annonce ses résultats pour le premier trimestre clos le 31 ma..
More news
Chart XVIVO PERFUSION AB (PUBL)
Duration : Period :
Xvivo Perfusion AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XVIVO PERFUSION AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 236,50 SEK
Average target price 385,75 SEK
Spread / Average Target 63,1%
EPS Revisions
Managers and Directors
Dag Andersson Chief Executive Officer
Kristoffer Nordstr÷m Chief Financial Officer & Head-investor Relations
G÷sta Per Johannesson Chairman
Andreas Wallinder Chief Medical Officer
Charlotte Walldal Director-Global Research & Development
Sector and Competitors
1st jan.Capi. (M$)
XVIVO PERFUSION AB (PUBL)-15.08%700
ABBOTT LABORATORIES-19.54%198 277
MEDTRONIC PLC-0.89%137 548
BECTON, DICKINSON AND COMPANY2.66%71 922
HOYA CORPORATION-22.41%37 902
BAXTER INTERNATIONAL INC.-14.69%36 873